Phase 2 Trial of Parotid-sparing Intensity-modulated Radiotherapy in Head and Neck Cancer
Researchers are evaluating the effectiveness of parotid-sparing intensity-modulated radiotherapy for reducing xerostomia in head and neck cancer.
Title: Phase II Study of Whole or Partial Parotid Sparing Intensity Modulated Radiotherapy in Patients With Head and Neck Cancers1
Principal Investigator: Christopher Nutting, PhD, MD, FRCR, MRCP, MB BS, Royal Marsden NHS Foundation Trust
Description: For this observational, phase 2 study (ClinicalTrials.gov Identifier: NCT02068313), researchers are evaluating the effectiveness of intensity-modulated radiotherapy for reducing xerostomia among patients with head and neck cancer, as well as determining the dose threshold for parotid glands.
The study's primary outcomes are xerostomia reduction and dose threshold for whole parotid glands and superficial lobes thereof. Secondary outcomes include toxicity, overall survival, disease-free survival, logo-regional control, and quality of life, all measured over 5 year periods.
For more study information, including inclusion and exclusion criteria, study locations, and contact information, visit https://clinicaltrials.gov/ct2/show/NCT02068313.
Status: This study is open and recruiting patients as of March 16, 2017.
This study is sponsored by the Royal Marsden NHS Foundation Trust.
- Clinicaltrials.gov. Phase II study of whole or partial parotid sparing intensity modulated radiotherapy in patients with head and neck cancers. NCT02068313. https://clinicaltrials.gov/ct2/show/NCT02068313. Accessed March 16, 2017.